Tuesday, October 6, 2026
Guggenheim started coverage of Xenon Pharmaceuticals (XENE) with a Buy rating and a price target of $73.
Friday, September 18, 2026
RBC Capital kept its Outperform rating on Xenon Pharmaceuticals (XENE) and lowered its price target to $70 from $81.
Wedbush kept its Outperform rating on Xenon Pharmaceuticals (XENE) with a price target of $55.
Wells Fargo kept its Overweight rating on Xenon Pharmaceuticals (XENE) with a price target of $64.
Deutsche Bank downgraded Xenon Pharmaceuticals (XENE) to Hold with a price target of $46.
Needham kept its Buy rating on Xenon Pharmaceuticals (XENE) and lowered its price target to $60 from $78.
Baird kept its Outperform rating on Xenon Pharmaceuticals (XENE) with a price target of $90.
Frequently asked questions
What is the latest news on XENE?
Oct 6, 2026: Guggenheim started coverage of Xenon Pharmaceuticals (XENE) with a Buy rating and a price target of $73. (Guggenheim) · Sep 18, 2026: RBC Capital kept its Outperform rating on Xenon Pharmaceuticals (XENE) and lowered its price target to $70 from $81. (RBC Capital) · Sep 18, 2026: Wedbush kept its Outperform rating on Xenon Pharmaceuticals (XENE) with a price target of $55. (Wedbush)
What are analysts saying about XENE?
Oct 6, 2026: Guggenheim started coverage of Xenon Pharmaceuticals (XENE) with a Buy rating and a price target of $73. · Sep 18, 2026: RBC Capital kept its Outperform rating on Xenon Pharmaceuticals (XENE) and lowered its price target to $70 from $81. · Sep 18, 2026: Wedbush kept its Outperform rating on Xenon Pharmaceuticals (XENE) with a price target of $55.
Get XENE news as it happens
Every headline, SEC filing and analyst action for XENE on your live chart, with important news marked and alerts when it matters.
Try SEPT Free